
ZSANQ
Healthcare · Biotechnology · $980 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 17, 2022 | Time not confirmed | -0.35 | 0.00 | +100.0% |
| Aug 26, 2022 | Before the open | -0.70 | 0.00 | +100.0% |
| May 13, 2022 | After the close | -1.75 | -1.76 | -0.6% |
| Mar 17, 2022 | After the close | -1.57 | -2.10 | -33.8% |
| Nov 10, 2021 | After the close | -2.68 | -2.45 | +8.6% |
| Aug 10, 2021 | After the close | -2.68 | -2.10 | +21.6% |
| May 12, 2021 | After the close | -2.68 | -2.80 | -4.5% |
| Mar 11, 2021 | After the close | -3.32 | -2.80 | +15.7% |
| Nov 13, 2020 | After the close | -3.38 | -3.85 | -13.9% |
| Aug 6, 2020 | Before the open | -4.90 | -4.90 | 0.0% |
| May 14, 2020 | After the close | -8.87 | -8.40 | +5.3% |
| Mar 13, 2020 | Before the open | -0.47 | -0.45 | +4.3% |
| Nov 14, 2019 | After the close | -0.58 |
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont,…
| -0.55 |
| +5.2% |
| Aug 14, 2019 | After the close | -0.56 | -0.55 | +1.8% |
| May 14, 2019 | After the close | -0.78 | -0.79 | -1.3% |
| Mar 14, 2019 | After the close | -0.69 | -0.85 | -23.2% |
| Nov 14, 2018 | After the close | -0.70 | -0.68 | +2.9% |
| Aug 9, 2018 | After the close | -0.89 | -0.75 | +15.7% |
| Apr 30, 2018 | After the close | -5.40 | -4.16 | +23.0% |
| Mar 12, 2018 | Before the open | -4.80 | -3.80 | +20.8% |